Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.